ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
77 hedge funds and large institutions have $195M invested in Adaptimmune Therapeutics in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 16 increasing their positions, 23 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
15% less capital invested
Capital invested by funds: $229M → $195M (-$34.2M)
20% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 15
30% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 23
Holders
77
Holding in Top 10
1
Calls
$219K
Puts
$70K
Top Buyers
| 1 | +$11.4M | |
| 2 | +$794K | |
| 3 | +$510K | |
| 4 |
Barclays
London,
United Kingdom
|
+$430K |
| 5 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$425K |
Top Sellers
| 1 | -$2.26M | |
| 2 | -$764K | |
| 3 | -$573K | |
| 4 |
Two Sigma Investments
New York
|
-$544K |
| 5 |
Rafferty Asset Management
New York
|
-$542K |